Adaptimmune Therapeutics - ADAP Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ADAP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADAP, but not buy additional shares or sell existing shares.
View ADAP analyst ratings or view top-rated stocks.

4 equities research analysts have issued 1 year price targets for Adaptimmune Therapeutics' stock. Their ADAP share price forecasts range from $3.00 to $15.00. On average, they expect the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 282.9% from the stock's current price.
View analysts price targets for ADAP or view top-rated stocks among Wall Street analysts.

Adaptimmune Therapeutics' stock was trading at $3.75 at the beginning of 2022. Since then, ADAP shares have decreased by 40.8% and is now trading at $2.22.
View the best growth stocks for 2022 here.

Adaptimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ADAP earnings forecast.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) issued its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.04. The biotechnology company earned $1.20 million during the quarter, compared to analysts' expectations of $1.20 million. Adaptimmune Therapeutics had a negative net margin of 1,500.43% and a negative trailing twelve-month return on equity of 93.64%. During the same period last year, the firm posted ($0.23) earnings per share.

6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP), Micron Technology (MU), BlackRock (BLK), Cara Therapeutics (CARA) and Chipotle Mexican Grill (CMG).

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Adaptimmune Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (9.46%) and Vigilare Wealth Management (0.03%). Insiders that own company stock include Adrian Rawcliffe, Elliot Norry, Gavin Wood, James Noble, John Lunger, Lawrence M Alleva, Peter W Sonsini, William C Bertrand Jr and William C Bertrand, Jr.
View institutional ownership trends.

Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADAP stock can currently be purchased for approximately $2.22.

Adaptimmune Therapeutics (NASDAQ:ADAP) has a market capitalization of $359.68 million and generates $6.15 million in revenue each year. The biotechnology company earns $-158,090,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

Adaptimmune Therapeutics employs 494 workers across the globe.

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The official website for the company is www.adaptimmune.com. The biotechnology company can be reached via phone at 441235430000, via email at ir@adaptimmune.com, or via fax at 44-12-3543-0001.